eprintid: 10071541
rev_number: 17
eprint_status: archive
userid: 608
dir: disk0/10/07/15/41
datestamp: 2019-04-03 16:24:48
lastmod: 2021-10-01 23:52:32
status_changed: 2019-04-03 16:24:48
type: article
metadata_visibility: show
creators_name: Andersson, A
creators_name: Remnestål, J
creators_name: Nellgård, B
creators_name: Vunk, H
creators_name: Kotol, D
creators_name: Edfors, F
creators_name: Uhlén, M
creators_name: Schwenk, JM
creators_name: Ilag, LL
creators_name: Zetterberg, H
creators_name: Blennow, K
creators_name: Månberg, A
creators_name: Nilsson, P
creators_name: Fredolini, C
title: Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease
ispublished: pub
divisions: UCL
divisions: B02
divisions: C07
divisions: D07
divisions: F86
keywords: AD, Alzheimer's disease, Biomarkers, Cerebrospinal fluid, Parallel reaction monitoring (PRM), Suspension bead array (SBA)
note: Copyright © 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
abstract: Detailed knowledge of protein changes in cerebrospinal fluid (CSF) across healthy and diseased individuals would provide a better understanding of the onset and progression of neurodegenerative disorders. In this study, we selected 20 brain-enriched proteins previously identified in CSF by antibody suspension bead arrays (SBA) to be potentially biomarkers for Alzheimer's disease (AD) and verified these using an orthogonal approach. We examined the same set of 94 CSF samples from patients affected by AD (including preclinical and prodromal), mild cognitive impairment (MCI), non-AD dementia and healthy individuals, which had previously been analyzed by SBA. Twenty-eight parallel reaction monitoring (PRM) assays were developed and 13 of them could be validated for protein quantification. Antibody profiles were verified by PRM. For seven proteins, the antibody profiles were highly correlated with the PRM results (r > 0.7) and GAP43, VCAM1 and PSAP were identified as potential markers of preclinical AD. In conclusion, we demonstrate the usefulness of targeted mass spectrometry as a tool for the orthogonal verification of antibody profiling data, suggesting that these complementary methods can be successfully applied for comprehensive exploration of CSF protein levels in neurodegenerative disorders.
date: 2019-07
date_type: published
official_url: http://doi.org/10.1016/j.cca.2019.03.243
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1642007
doi: 10.1016/j.cca.2019.03.243
pii: S0009-8981(19)30348-1
lyricists_name: Zetterberg, Henrik
lyricists_id: HZETT94
actors_name: Flynn, Bernadette
actors_id: BFFLY94
actors_role: owner
full_text_status: public
publication: Clinica Chimica Acta
volume: 494
pagerange: 79-93
event_location: Netherlands
issn: 1873-3492
citation:        Andersson, A;    Remnestål, J;    Nellgård, B;    Vunk, H;    Kotol, D;    Edfors, F;    Uhlén, M;                             ... Fredolini, C; + view all <#>        Andersson, A;  Remnestål, J;  Nellgård, B;  Vunk, H;  Kotol, D;  Edfors, F;  Uhlén, M;  Schwenk, JM;  Ilag, LL;  Zetterberg, H;  Blennow, K;  Månberg, A;  Nilsson, P;  Fredolini, C;   - view fewer <#>    (2019)    Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease.                   Clinica Chimica Acta , 494    pp. 79-93.    10.1016/j.cca.2019.03.243 <https://doi.org/10.1016/j.cca.2019.03.243>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10071541/1/1-s2.0-S0009898119303481-main.pdf